A Case of Dextrocardia Following Maternal Exposure to Generic Fingolimod During the First Trimester of Pregnancy Publisher Pubmed



Navardi S^{1, 2} ; Sahraian MA^{1, 2} Show Affiliations
Source: Multiple Sclerosis and Related Disorders Published:2018

Abstract

Fingolimod, taken orally once per day, is approved for the treatment of relapsing-remitting multiple sclerosis (MS). It should be stopped at least two months before conception as it is not considered safe during pregnancy or when breast feeding. In vitro and animal studies have found a possibly increased risk of congenital abnormalities following exposure to Fingolimod. Here, we report a 34-year-old female, with a 10-year history of MS who had unexpected pregnancy with exposure to generic Fingolimod during the first 7 weeks. The infant was born with dextrocardia, but without any further structural cardiac or other abnormalities © 2018 Elsevier B.V.